ArticleInternational journal of biological sciences2026
Reprogramming Transcriptional Networks via CREB1 Lactylation at K122 Activates HMGB1-Mediated NETosis and Chemoresistance.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin resistance remains a major obstacle in ovarian cancer treatment. While lactate-rich tumor microenvironments promote chemoresistance, the role of lysine lactylation (Kla) in this process remains poorly understood. Here, we identify CREB1 lactylation at K122 as a pivotal epigenetic driver of cisplatin resistance. Through quantitative lactyl-proteomics, we found CREB1 K122 as a hyperlactylated site specifically enriched in cisplatin-resistant ovarian cancer cells and patient tissues. This modification is dynamically regulated by the opposing activities of p300 (writer) and SIRT1 (eraser). Functionally, a lactylation-mimetic CREB1 mutant (K122Q) conferred robust resistance, enhancing cell survival and tumor growth, whereas a lactylation-deficient mutant (K122R) sensitized cells to cisplatin. Mechanistically, CUT&Tag analysis revealed that K122la remodels chromatin architecture, redistributing CREB1 binding from promoters to distal enhancers and substantially expanding its target repertoire. This transcriptional rewiring specifically activated neutrophil extracellular trap (NETosis) programs, with high mobility group box 1 (HMGB1) emerging as a key downstream effector. Lactylated CREB1 promotes HMGB1 transcription and subsequent exosomal secretion into the tumor microenvironment. Secreted HMGB1 then engages Toll-like receptor 4 (TLR4) on neutrophils to trigger NETosis, establishing a chemoprotective niche. Clinically, cisplatin-resistant patients exhibited elevated tumor K122 lactylation and serum exosomal HMGB1 levels. Most importantly, we developed a tumor-targeted lipid nanoparticle (LNP) system delivering a lactylation-deficient CREB1 K122R competitive peptide. This nanotherapeutic approach, particularly when combined with cisplatin, potently suppressed tumor growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.